Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring
Abstract Background Tenofovir-diphosphate (TFV-DP) measured in dried blood spots (DBS) and tenofovir (TFV) measured in urine/plasma have been used to measure TFV-based oral pre-exposure prophylaxis (PrEP) adherence. However, there are limited data comparing these 3 metrics and their appropriate use...
Gespeichert in:
| Veröffentlicht in: | Open Forum Infectious Diseases 2022-08, Vol.9 (8), p.ofac405 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | ofac405 |
| container_title | Open Forum Infectious Diseases |
| container_volume | 9 |
| creator | Niu, Xin Kubiak, Rachel W Siriprakaisil, Oraphan Klinbuyaem, Virat Sukrakanchana, Pra ornsuda Cressey, Ratchada Okochi, Hideaki Gandhi, Monica Cressey, Tim R Drain, Paul K |
| description | Abstract
Background
Tenofovir-diphosphate (TFV-DP) measured in dried blood spots (DBS) and tenofovir (TFV) measured in urine/plasma have been used to measure TFV-based oral pre-exposure prophylaxis (PrEP) adherence. However, there are limited data comparing these 3 metrics and their appropriate use for PrEP adherence monitoring.
Methods
We collected DBS, urine, and plasma samples from HIV-negative adults randomized to a low (2 doses/week), moderate (4 doses/week), or perfect (7 doses/week) adherence group (via directly observed therapy) of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 6 weeks, followed by a 4-week washout phase. Drug concentrations were measured using liquid chromatography tandem mass spectrometry. Linear mixed-effects modeling was used to examine associations between drug concentrations and dosing time.
Results
Among 28 participants, the median age was 33 years, and 12 (43%) were female. At steady state, 25th percentile TFV-DP concentrations were 466, 779, and 1375 fmol/3 mm punch in the low, moderate, and perfect adherence group, respectively. Correlation was stronger between quantifiable TFV-DP and plasma TFV (r = 0.65; P |
| doi_str_mv | 10.1093/ofid/ofac405 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9394764</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A776147252</galeid><oup_id>10.1093/ofid/ofac405</oup_id><sourcerecordid>A776147252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-b0825c6514bb7fd7519c4e03dc56c7f1e53b3928cbd34431a4b8068a05e8371c3</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhSMEolXpjTPyDQ6ktWM7Ti5IS0sBqaiVaM-W40w2Rokn2MmqPfDf69Uuq3JBluzR-HtPM3pZ9pbRM0Zrfo6da9NlrKDyRXZc8KLKq1qql8_qo-w0xl-UUsaopKp-nR3xklLBmTzO_tyBxw43LuSXbuoxTr2ZgThPLoODlnweEFvyc8I5kk0kB3pL3Afn4fx2MHE0pMNAboIZyG0AeJgwLgFSjVP_OJgHF8mq7SGAt0B-oHczJvH6TfaqM0OE0_17kt1ffbm7-JZf33z9frG6zq2o-Jw3tCqkLSUTTaO6VklWWwGUt1aWVnUMJG94XVS2ablIexnRVLSsDJVQccUsP8k-7XynpRmhteDnNKqeghtNeNRonP73x7ter3Gja14LVYpk8GFvEPD3AnHWo4sWhsF4wCXqQtFSsVpxmtCzHbo2A2jnO0yONp0WRmfRQ-dSf6VUyYQqZJEEH3cCGzDGAN1hLkb1NmW9TVnvU074u-e7HOC_mSbg_Q7AZfq_1RPQRLQf</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2706719730</pqid></control><display><type>article</type><title>Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Niu, Xin ; Kubiak, Rachel W ; Siriprakaisil, Oraphan ; Klinbuyaem, Virat ; Sukrakanchana, Pra ornsuda ; Cressey, Ratchada ; Okochi, Hideaki ; Gandhi, Monica ; Cressey, Tim R ; Drain, Paul K</creator><creatorcontrib>Niu, Xin ; Kubiak, Rachel W ; Siriprakaisil, Oraphan ; Klinbuyaem, Virat ; Sukrakanchana, Pra ornsuda ; Cressey, Ratchada ; Okochi, Hideaki ; Gandhi, Monica ; Cressey, Tim R ; Drain, Paul K</creatorcontrib><description>Abstract
Background
Tenofovir-diphosphate (TFV-DP) measured in dried blood spots (DBS) and tenofovir (TFV) measured in urine/plasma have been used to measure TFV-based oral pre-exposure prophylaxis (PrEP) adherence. However, there are limited data comparing these 3 metrics and their appropriate use for PrEP adherence monitoring.
Methods
We collected DBS, urine, and plasma samples from HIV-negative adults randomized to a low (2 doses/week), moderate (4 doses/week), or perfect (7 doses/week) adherence group (via directly observed therapy) of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 6 weeks, followed by a 4-week washout phase. Drug concentrations were measured using liquid chromatography tandem mass spectrometry. Linear mixed-effects modeling was used to examine associations between drug concentrations and dosing time.
Results
Among 28 participants, the median age was 33 years, and 12 (43%) were female. At steady state, 25th percentile TFV-DP concentrations were 466, 779, and 1375 fmol/3 mm punch in the low, moderate, and perfect adherence group, respectively. Correlation was stronger between quantifiable TFV-DP and plasma TFV (r = 0.65; P < .01) than between TFV-DP and urine TFV (r = 0.50; P < .01). Among all participants, each additional week of cumulative dosing on average led to a mean increase of 158 fmol/3 mm punch (P < .001) in TFV-DP during the dosing phase. Each additional day after the last dose was associated with 43 fmol/3 mm punch lower TFV-DP (P = .07).
Conclusions
TFV-DP levels in DBS provide valuable insight into both dosing recency and cumulative doses from variable adherence patterns. Our observed benchmark TFV-DP concentrations were slightly higher than prior predicted estimates based on convenience samples.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofac405</identifier><identifier>PMID: 36004315</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Analysis ; Emtricitabine ; Liquid chromatography ; Major ; Mass spectrometry ; Patient compliance ; Tenofovir</subject><ispartof>Open Forum Infectious Diseases, 2022-08, Vol.9 (8), p.ofac405</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022</rights><rights>The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</rights><rights>COPYRIGHT 2022 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-b0825c6514bb7fd7519c4e03dc56c7f1e53b3928cbd34431a4b8068a05e8371c3</citedby><cites>FETCH-LOGICAL-c483t-b0825c6514bb7fd7519c4e03dc56c7f1e53b3928cbd34431a4b8068a05e8371c3</cites><orcidid>0000-0002-7025-1994 ; 0000-0002-9569-4097</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394764/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394764/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,1605,27926,27927,53793,53795</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36004315$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niu, Xin</creatorcontrib><creatorcontrib>Kubiak, Rachel W</creatorcontrib><creatorcontrib>Siriprakaisil, Oraphan</creatorcontrib><creatorcontrib>Klinbuyaem, Virat</creatorcontrib><creatorcontrib>Sukrakanchana, Pra ornsuda</creatorcontrib><creatorcontrib>Cressey, Ratchada</creatorcontrib><creatorcontrib>Okochi, Hideaki</creatorcontrib><creatorcontrib>Gandhi, Monica</creatorcontrib><creatorcontrib>Cressey, Tim R</creatorcontrib><creatorcontrib>Drain, Paul K</creatorcontrib><title>Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring</title><title>Open Forum Infectious Diseases</title><addtitle>Open Forum Infect Dis</addtitle><description>Abstract
Background
Tenofovir-diphosphate (TFV-DP) measured in dried blood spots (DBS) and tenofovir (TFV) measured in urine/plasma have been used to measure TFV-based oral pre-exposure prophylaxis (PrEP) adherence. However, there are limited data comparing these 3 metrics and their appropriate use for PrEP adherence monitoring.
Methods
We collected DBS, urine, and plasma samples from HIV-negative adults randomized to a low (2 doses/week), moderate (4 doses/week), or perfect (7 doses/week) adherence group (via directly observed therapy) of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 6 weeks, followed by a 4-week washout phase. Drug concentrations were measured using liquid chromatography tandem mass spectrometry. Linear mixed-effects modeling was used to examine associations between drug concentrations and dosing time.
Results
Among 28 participants, the median age was 33 years, and 12 (43%) were female. At steady state, 25th percentile TFV-DP concentrations were 466, 779, and 1375 fmol/3 mm punch in the low, moderate, and perfect adherence group, respectively. Correlation was stronger between quantifiable TFV-DP and plasma TFV (r = 0.65; P < .01) than between TFV-DP and urine TFV (r = 0.50; P < .01). Among all participants, each additional week of cumulative dosing on average led to a mean increase of 158 fmol/3 mm punch (P < .001) in TFV-DP during the dosing phase. Each additional day after the last dose was associated with 43 fmol/3 mm punch lower TFV-DP (P = .07).
Conclusions
TFV-DP levels in DBS provide valuable insight into both dosing recency and cumulative doses from variable adherence patterns. Our observed benchmark TFV-DP concentrations were slightly higher than prior predicted estimates based on convenience samples.</description><subject>Analysis</subject><subject>Emtricitabine</subject><subject>Liquid chromatography</subject><subject>Major</subject><subject>Mass spectrometry</subject><subject>Patient compliance</subject><subject>Tenofovir</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kUFv1DAQhSMEolXpjTPyDQ6ktWM7Ti5IS0sBqaiVaM-W40w2Rokn2MmqPfDf69Uuq3JBluzR-HtPM3pZ9pbRM0Zrfo6da9NlrKDyRXZc8KLKq1qql8_qo-w0xl-UUsaopKp-nR3xklLBmTzO_tyBxw43LuSXbuoxTr2ZgThPLoODlnweEFvyc8I5kk0kB3pL3Afn4fx2MHE0pMNAboIZyG0AeJgwLgFSjVP_OJgHF8mq7SGAt0B-oHczJvH6TfaqM0OE0_17kt1ffbm7-JZf33z9frG6zq2o-Jw3tCqkLSUTTaO6VklWWwGUt1aWVnUMJG94XVS2ablIexnRVLSsDJVQccUsP8k-7XynpRmhteDnNKqeghtNeNRonP73x7ter3Gja14LVYpk8GFvEPD3AnHWo4sWhsF4wCXqQtFSsVpxmtCzHbo2A2jnO0yONp0WRmfRQ-dSf6VUyYQqZJEEH3cCGzDGAN1hLkb1NmW9TVnvU074u-e7HOC_mSbg_Q7AZfq_1RPQRLQf</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Niu, Xin</creator><creator>Kubiak, Rachel W</creator><creator>Siriprakaisil, Oraphan</creator><creator>Klinbuyaem, Virat</creator><creator>Sukrakanchana, Pra ornsuda</creator><creator>Cressey, Ratchada</creator><creator>Okochi, Hideaki</creator><creator>Gandhi, Monica</creator><creator>Cressey, Tim R</creator><creator>Drain, Paul K</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7025-1994</orcidid><orcidid>https://orcid.org/0000-0002-9569-4097</orcidid></search><sort><creationdate>20220801</creationdate><title>Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring</title><author>Niu, Xin ; Kubiak, Rachel W ; Siriprakaisil, Oraphan ; Klinbuyaem, Virat ; Sukrakanchana, Pra ornsuda ; Cressey, Ratchada ; Okochi, Hideaki ; Gandhi, Monica ; Cressey, Tim R ; Drain, Paul K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-b0825c6514bb7fd7519c4e03dc56c7f1e53b3928cbd34431a4b8068a05e8371c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Emtricitabine</topic><topic>Liquid chromatography</topic><topic>Major</topic><topic>Mass spectrometry</topic><topic>Patient compliance</topic><topic>Tenofovir</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niu, Xin</creatorcontrib><creatorcontrib>Kubiak, Rachel W</creatorcontrib><creatorcontrib>Siriprakaisil, Oraphan</creatorcontrib><creatorcontrib>Klinbuyaem, Virat</creatorcontrib><creatorcontrib>Sukrakanchana, Pra ornsuda</creatorcontrib><creatorcontrib>Cressey, Ratchada</creatorcontrib><creatorcontrib>Okochi, Hideaki</creatorcontrib><creatorcontrib>Gandhi, Monica</creatorcontrib><creatorcontrib>Cressey, Tim R</creatorcontrib><creatorcontrib>Drain, Paul K</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open Forum Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niu, Xin</au><au>Kubiak, Rachel W</au><au>Siriprakaisil, Oraphan</au><au>Klinbuyaem, Virat</au><au>Sukrakanchana, Pra ornsuda</au><au>Cressey, Ratchada</au><au>Okochi, Hideaki</au><au>Gandhi, Monica</au><au>Cressey, Tim R</au><au>Drain, Paul K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring</atitle><jtitle>Open Forum Infectious Diseases</jtitle><addtitle>Open Forum Infect Dis</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>9</volume><issue>8</issue><spage>ofac405</spage><pages>ofac405-</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract
Background
Tenofovir-diphosphate (TFV-DP) measured in dried blood spots (DBS) and tenofovir (TFV) measured in urine/plasma have been used to measure TFV-based oral pre-exposure prophylaxis (PrEP) adherence. However, there are limited data comparing these 3 metrics and their appropriate use for PrEP adherence monitoring.
Methods
We collected DBS, urine, and plasma samples from HIV-negative adults randomized to a low (2 doses/week), moderate (4 doses/week), or perfect (7 doses/week) adherence group (via directly observed therapy) of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 6 weeks, followed by a 4-week washout phase. Drug concentrations were measured using liquid chromatography tandem mass spectrometry. Linear mixed-effects modeling was used to examine associations between drug concentrations and dosing time.
Results
Among 28 participants, the median age was 33 years, and 12 (43%) were female. At steady state, 25th percentile TFV-DP concentrations were 466, 779, and 1375 fmol/3 mm punch in the low, moderate, and perfect adherence group, respectively. Correlation was stronger between quantifiable TFV-DP and plasma TFV (r = 0.65; P < .01) than between TFV-DP and urine TFV (r = 0.50; P < .01). Among all participants, each additional week of cumulative dosing on average led to a mean increase of 158 fmol/3 mm punch (P < .001) in TFV-DP during the dosing phase. Each additional day after the last dose was associated with 43 fmol/3 mm punch lower TFV-DP (P = .07).
Conclusions
TFV-DP levels in DBS provide valuable insight into both dosing recency and cumulative doses from variable adherence patterns. Our observed benchmark TFV-DP concentrations were slightly higher than prior predicted estimates based on convenience samples.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>36004315</pmid><doi>10.1093/ofid/ofac405</doi><orcidid>https://orcid.org/0000-0002-7025-1994</orcidid><orcidid>https://orcid.org/0000-0002-9569-4097</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2328-8957 |
| ispartof | Open Forum Infectious Diseases, 2022-08, Vol.9 (8), p.ofac405 |
| issn | 2328-8957 2328-8957 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9394764 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central |
| subjects | Analysis Emtricitabine Liquid chromatography Major Mass spectrometry Patient compliance Tenofovir |
| title | Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T05%3A50%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tenofovir-Diphosphate%20in%20Dried%20Blood%20Spots%20vs%20Tenofovir%20in%20Urine/Plasma%20for%20Oral%20Preexposure%20Prophylaxis%20Adherence%20Monitoring&rft.jtitle=Open%20Forum%20Infectious%20Diseases&rft.au=Niu,%20Xin&rft.date=2022-08-01&rft.volume=9&rft.issue=8&rft.spage=ofac405&rft.pages=ofac405-&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofac405&rft_dat=%3Cgale_pubme%3EA776147252%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2706719730&rft_id=info:pmid/36004315&rft_galeid=A776147252&rft_oup_id=10.1093/ofid/ofac405&rfr_iscdi=true |